Actively Recruiting
Study of Twice Daily Cannabidiol Epidiolex to Treat Urinary Incontinence in Adults with Spinal Cord Injury
Led by University of Wisconsin, Madison · Updated on 2026-03-04
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether Cannabidiol CBD, specifically Epidiolex, can improve urinary incontinence and related symptoms in adults who have recently experienced spinal cord injury SCI. This pilot study focuses on people with neurogenic lower urinary tract dysfunction after spinal shock has resolved. The study aims to establish the feasibility of using CBD in this context and is sponsored by the University of Wisconsin, Madison. Participants will take a dose of 100 mg of purified CBD twice daily for 90 days. There is a single study group where all participants receive CBD treatment during this period. The study tracks adherence to the medication and monitors symptoms related to urinary incontinence and neurogenic bladder. During the 90-day treatment, participants will complete a 72-hour voiding diary and report any adverse events for up to 120 days. Researchers will assess changes in urinary incontinence episodes and symptoms, as well as how well participants follow the CBD regimen. Safety and treatment effects will be closely monitored, with the total participation lasting approximately 3 to 4 months.
CONDITIONS
Brief Title
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
Research Team
M
Maria Flory
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
